Cargando…

Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811

INTRODUCTION: Operation on the infrarenal aorta and large arteries of the lower extremities may cause rhabdomyolysis of the skeletal muscle, which in turn may induce remote kidney injury. NIM-811 (N-metyl-4-isoleucine-cyclosporine) is a mitochondria specific drug, which can prevent ischemic-reperfus...

Descripción completa

Detalles Bibliográficos
Autores principales: Garbaisz, David, Turoczi, Zsolt, Aranyi, Peter, Fulop, Andras, Rosero, Oliver, Hermesz, Edit, Ferencz, Agnes, Lotz, Gabor, Harsanyi, Laszlo, Szijarto, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072765/
https://www.ncbi.nlm.nih.gov/pubmed/24968303
http://dx.doi.org/10.1371/journal.pone.0101067
_version_ 1782323017720791040
author Garbaisz, David
Turoczi, Zsolt
Aranyi, Peter
Fulop, Andras
Rosero, Oliver
Hermesz, Edit
Ferencz, Agnes
Lotz, Gabor
Harsanyi, Laszlo
Szijarto, Attila
author_facet Garbaisz, David
Turoczi, Zsolt
Aranyi, Peter
Fulop, Andras
Rosero, Oliver
Hermesz, Edit
Ferencz, Agnes
Lotz, Gabor
Harsanyi, Laszlo
Szijarto, Attila
author_sort Garbaisz, David
collection PubMed
description INTRODUCTION: Operation on the infrarenal aorta and large arteries of the lower extremities may cause rhabdomyolysis of the skeletal muscle, which in turn may induce remote kidney injury. NIM-811 (N-metyl-4-isoleucine-cyclosporine) is a mitochondria specific drug, which can prevent ischemic-reperfusion (IR) injury, by inhibiting mitochondrial permeability transition pores (mPTP). OBJECTIVES: Our aim was to reduce damages in the skeletal muscle and the kidney after IR of the lower limb with NIM-811. MATERIALS AND METHODS: Wistar rats underwent 180 minutes of bilateral lower limb ischemia and 240 minutes of reperfusion. Four animal groups were formed called Sham (receiving vehicle and sham surgery), NIM-Sham (receiving NIM-811 and sham surgery), IR (receiving vehicle and surgery), and NIM-IR (receiving NIM-811 and surgery). Serum, urine and histological samples were taken at the end of reperfusion. NADH-tetrazolium staining, muscle Wet/Dry (W/D) ratio calculations, laser Doppler-flowmetry (LDF) and mean arterial pressure (MAP) monitoring were performed. Renal peroxynitrite concentration, serum TNF-α and IL-6 levels were measured. RESULTS: Less significant histopathological changes were observable in the NIM-IR group as compared with the IR group. Serum K(+) and necroenzyme levels were significantly lower in the NIM-IR group than in the IR group (LDH: p<0.001; CK: p<0.001; K(+): p = 0.017). Muscle mitochondrial viability proved to be significantly higher (p = 0.001) and renal function parameters were significantly better (creatinine: p = 0.016; FENa: p<0.001) in the NIM-IR group in comparison to the IR group. Serum TNF-α and IL-6 levels were significantly lower (TNF-α: p = 0.003, IL-6: p = 0.040) as well as W/D ratio and peroxynitrite concentration were significantly lower (p = 0.014; p<0.001) in the NIM-IR group than in the IR group. CONCLUSION: NIM-811 could have the potential of reducing rhabdomyolysis and impairment of the kidney after lower limb IR injury.
format Online
Article
Text
id pubmed-4072765
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40727652014-07-02 Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811 Garbaisz, David Turoczi, Zsolt Aranyi, Peter Fulop, Andras Rosero, Oliver Hermesz, Edit Ferencz, Agnes Lotz, Gabor Harsanyi, Laszlo Szijarto, Attila PLoS One Research Article INTRODUCTION: Operation on the infrarenal aorta and large arteries of the lower extremities may cause rhabdomyolysis of the skeletal muscle, which in turn may induce remote kidney injury. NIM-811 (N-metyl-4-isoleucine-cyclosporine) is a mitochondria specific drug, which can prevent ischemic-reperfusion (IR) injury, by inhibiting mitochondrial permeability transition pores (mPTP). OBJECTIVES: Our aim was to reduce damages in the skeletal muscle and the kidney after IR of the lower limb with NIM-811. MATERIALS AND METHODS: Wistar rats underwent 180 minutes of bilateral lower limb ischemia and 240 minutes of reperfusion. Four animal groups were formed called Sham (receiving vehicle and sham surgery), NIM-Sham (receiving NIM-811 and sham surgery), IR (receiving vehicle and surgery), and NIM-IR (receiving NIM-811 and surgery). Serum, urine and histological samples were taken at the end of reperfusion. NADH-tetrazolium staining, muscle Wet/Dry (W/D) ratio calculations, laser Doppler-flowmetry (LDF) and mean arterial pressure (MAP) monitoring were performed. Renal peroxynitrite concentration, serum TNF-α and IL-6 levels were measured. RESULTS: Less significant histopathological changes were observable in the NIM-IR group as compared with the IR group. Serum K(+) and necroenzyme levels were significantly lower in the NIM-IR group than in the IR group (LDH: p<0.001; CK: p<0.001; K(+): p = 0.017). Muscle mitochondrial viability proved to be significantly higher (p = 0.001) and renal function parameters were significantly better (creatinine: p = 0.016; FENa: p<0.001) in the NIM-IR group in comparison to the IR group. Serum TNF-α and IL-6 levels were significantly lower (TNF-α: p = 0.003, IL-6: p = 0.040) as well as W/D ratio and peroxynitrite concentration were significantly lower (p = 0.014; p<0.001) in the NIM-IR group than in the IR group. CONCLUSION: NIM-811 could have the potential of reducing rhabdomyolysis and impairment of the kidney after lower limb IR injury. Public Library of Science 2014-06-26 /pmc/articles/PMC4072765/ /pubmed/24968303 http://dx.doi.org/10.1371/journal.pone.0101067 Text en © 2014 Garbaisz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Garbaisz, David
Turoczi, Zsolt
Aranyi, Peter
Fulop, Andras
Rosero, Oliver
Hermesz, Edit
Ferencz, Agnes
Lotz, Gabor
Harsanyi, Laszlo
Szijarto, Attila
Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811
title Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811
title_full Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811
title_fullStr Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811
title_full_unstemmed Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811
title_short Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-Reperfusion Using mPTP Inhibitor NIM-811
title_sort attenuation of skeletal muscle and renal injury to the lower limb following ischemia-reperfusion using mptp inhibitor nim-811
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072765/
https://www.ncbi.nlm.nih.gov/pubmed/24968303
http://dx.doi.org/10.1371/journal.pone.0101067
work_keys_str_mv AT garbaiszdavid attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT turoczizsolt attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT aranyipeter attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT fulopandras attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT roserooliver attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT hermeszedit attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT ferenczagnes attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT lotzgabor attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT harsanyilaszlo attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811
AT szijartoattila attenuationofskeletalmuscleandrenalinjurytothelowerlimbfollowingischemiareperfusionusingmptpinhibitornim811